No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Polpharma Inks Licensing Deal with MS Pharma for Guselkumab, Ocrelizumab and Vedolizumab Biosimilars
On 2 September 2025, Polpharma Biologics S.A. and MS Pharma announced that they have entered into licensing agreements for the commercialisation of proposed biosimilar candidates to…